Antitumor agents. 2. Synthesis and cytotoxic evaluation of 10- bromorutaecarpine

Chinese Pharmaceutical Journal

Volumn 51, Issue 3, 1999, Pages 219-225

  Yang, Li Ming ^a,b   Lin, Shwu Jiuan ^b   Lin, Lie Chwen ^a   Kuo, Yao Haur ^a  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antitumor; Evodia rutaecarpa; Quinazolinocarboline alkaloid; Rutaecarpine

Indexed keywords

10 BROMORUTAECARPINE; ANTINEOPLASTIC AGENT; RUTAECARPINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; OVARY CANCER; TUMOR CELL LINE;

EID: 0032768680     PISSN: 10161015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Asahina, Y.; Ishimasa, S. Synthese des Rutaecarpins. Yakugaku Zasshi, 1926, 534, 61-63.
2. Li, S. C. Pentssu Kang Mu, 1596, Chapter 32.
3. Bergman, J. The Alkaloids; Brossi, A.R., Ed.; Academic Press: New York, 1983, 21, pp 29-54.
4. Yang, L. M.; Chen, C. F.; Lee, K. H. Synthesis of Rutaecarpine and Cytotoxic Analogues. Bioorg. Med. Chem. Lett. 1995, 5, 465-468.
5. Still, I. W. J.; Strautmanis, J. R. Approaches to the Tetracyclic Eudistomins: the Synthesis of N-(10)-acetyleudistomin L. Can. J. Chem. 1990, 68, 1408-1419.
6. Büchi, G.; Mak, C. P. Nitro Olefination of Indoles and Some Substituted Benzenes with 1-Dimethylamino-2-nitroethylene. J. Org. Chem. 1977, 42, 1784-1786.
7. Mahboobi, S. Synthesis of the Alkaloid Woodinine. Arch. Pharm. 1992, 325, 249-250.
8. Ho, B. T.; Mclsaac, W. M.; Tansey, L. W. Hydroxyindole-O-methyltransferase III: Influence of the Phenyl Moiety on the Inhibitory Activities of Some N-Acetyltryptamines. J. Pharm. Sci. 1969, 58, 563-566.
9. Bergman, J.; Bergman, S. Studies of Rutaecarpine and Related Quinazolinocarboline Alkaloids. J. Org. Chem. 1985, 50, 1246-1255.
10. Bergman, J.; Bergman, S. Synthesis of Rutaecarpine and Related Indole Alkaloids. Heterocycles 1981, 16, 347-350.
11. Boyd, M. R.; Paull, K. D. Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Dev. Res. 1995, 34, 91-109.
12. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: Cancer Drug Discovery and Development Program. Seminars Oncol. 1992, 19, 622-638.
13. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Boyd, M. Feasibility of a High-Flux Anti-Cancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
14. Boyd, M. R.; Paull, K. D.; Rubinstein, L. R. Data Display and Analysis Strategies for the NCI Disease-Oriented in vitro Antitumor Drug Screen. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development; Valeriote, F. A.; Corbett, T.; Baker, L.; Eds.; Kluwer Academic Publishers: Amsterdam, 1992; pp 11-34.
15. Acton, E. M.; Narayanan, V. L.; Risbood, P.; Shoemaker, R. H.; Vistica, D. T.; Boyd, M. R. Anticancer Specificity of Some Ellipticinium Salts Against Human Brain Tumors in vitro. J. Med. Chem. 1994, 37, 2185-2189.